FDA approves first drug Spinraza (nusinersen), for spinal muscular atrophy
FDA approves first drug for spinal muscular atrophy New therapy addresses unmet medical need for rare disease The U.S. Food and Drug Administration today approved Spinraza (nusinersen), the first drug approved to treat children and adults with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement. Spinraza is …